October 28, 2019

Salarius Pharmaceuticals and Aspire Capital Announce a $10.9M Common Stock Purchase Agreement

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022

HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it has entered into a $10.9 million common stock purchase agreement, including a $1.0 million initial common stock purchase, with Aspire Capital Fund, LLC, a Chicago-based institutional investor.


Jeremy Feffer LifeSci Advisors
Download PDF